Novo Nordisk A/S
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a NVO research report →
About the company
Novo Nordisk A/S is a global pharmaceutical firm dedicated to the investigation, creation, manufacturing, and distribution of medicinal products across a vast international footprint. Its market presence extends throughout Europe, the Middle East, Africa, various parts of Asia (including Mainland China, Hong Kong, and Taiwan), and North America. The company's operations are structured into two principal business units: Diabetes and Obesity Care, and Rare Disease.
- CEO
- Maziar Mike Doustdar
- IPO
- 1981
- Employees
- 77,406
- HQ
- Bagsvaerd, DK
Price Chart
- Market Cap
- $195.77B
- P/E
- 10.40
- P/S
- 3.87
- P/B
- 6.25
- EV/EBITDA
- 7.83
- Div Yield
- 4.10%
- Gross Margin
- 81.85%
- Op Margin
- 45.30%
- Net Margin
- 37.20%
- ROE
- 66.36%
- ROIC
- 32.20%
- Revenue
- $309.06B · 6.43%
- Net Income
- $102.43B · 1.43%
- EPS
- $23.06 · 1.72%
- Op Income
- $127.66B
- FCF YoY
- -58.38%
- 52W High
- $78.38
- 52W Low
- $35.12
- 50D MA
- $42.41
- 200D MA
- $48.41
- Beta
- 0.35
- Avg Volume
- 16.15M
AI snapshot
Six angles, distilled from the data.
The stock is in a multi-month recovery but still below its long-term trend. It trades above the 50-day average and well under the 200-day, with the share price far below the 52-week high and closer to the lower end of its yearly range.
Street sentiment is constructive but cautious: the consensus sits at Buy with a $45 target, only modestly above the current level. Recent action has skewed softer, with multiple downgrades since February and several target cuts, even as a few firms still rate the name positively.
The earnings profile remains mixed but resilient, with 5 beats in the last 7 quarters. Next-year EPS estimates point sharply higher to 21.47 from 4.26 TTM, so shareholders should watch whether obesity and diabetes momentum can keep supporting that step-up.
No notable insider activity. The recent transaction table is empty, so there is no discretionary buying or selling signal to read into.
Profitability is exceptional, led by an 83.2% gross margin and a 61.6% operating margin. Revenue grew 24% year over year and earnings grew 67.1%, while the balance sheet carries net debt of $104.0 billion against $26.96 billion of cash.
Novo Nordisk still stands out on margins and scale in obesity and diabetes, but the market is discounting slower leadership recovery versus peers. At about 10.2x earnings, the valuation sits at a clear discount to its growth profile and to many large-cap healthcare leaders.
Our NVO coverage
Recent articles, reports, and earnings notes.
Novo Nordisk (NVO): Obesity Growth vs. 2026 Pricing Pressure
Novo Nordisk remains a premier cardiometabolic franchise, but near-term pricing pressure and a weak 2026 outlook are tempering the story. The stock looks attractive for patient investors who can look through the reset and wait for obesity and pipeline reacceleration.
Novo Nordisk A/S (NVO) rises on Wegovy launch
Novo Nordisk A/S (NVO) rises as investors react to the UAE launch of the Wegovy pill and position ahead of ADA 2026. The move highlights renewed confidence in the company’s obesity franchise after a difficult year and a February guidance reset.
The GLP-1 trade is becoming a market-share war, not a rising-tide story
Investors still talk about obesity drugs like a category ETF, but the evidence now points to a leadership trade. Eli Lilly is widening the gap with stronger execution, better prescription momentum, and a more threatening pipeline just as Novo Nordisk faces pricing pressure and a weaker growth profile.
Want a deeper read on NVO?
Generate a full analyst-grade report — bull/bear case, price targets, valuation depth, and a complete financial breakdown.
Similar companies
Peers in the same neighborhood.
AI analysis · Last refreshed June 11, 2026 · Live quote · Not investment advice